This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, E. Articles by Lee, A. S. Search for Related Content PubMed PubMed Citation Articles by Lee, E. Articles by Lee, A. S.

GRP78 as a Novel Predictor of Responsiveness to Chemotherapy in Breast Cancer

Departments of ¹ Preventive Medicine, ² Pathology, ³ Medicine and Medical Oncology, and ⁴ Biochemistry and Molecular Biology, University of Southern California/Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, California and ⁵ The Cancer Center, University of Minnesota, Minneapolis, Minnesota

Requests for reprints: Amy S. Lee, Department of Biochemistry and Molecular Biology, University of Southern California/Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90089-9176. Phone: 323-865-0507; Fax: 323-865-0094; E-mail: amylee{at}usc.edu.

The discovery of predictive factors for chemoresistance is critical for improving adjuvant therapy for cancer patients. The 78-kDa glucose-regulated protein (GRP78), widely used as an indicator of the unfolded protein response (UPR), is induced in the tumor microenvironment. In vitro studies suggest that GRP78 confers chemoresistance to topoisomerase inhibitors, such as Adriamycin (doxorubicin). Here, we report on a retrospective cohort study of 127 stage II and III breast cancer patients who were treated with Adriamycin-based chemotherapy. Archival tumor specimens were available for analysis and the relationship of GRP78 expression level to "time to recurrence" (TTR), used as a surrogate marker for drug resistance, was examined. Our data show that 67% of the study subjects expressed high level of GRP78 in their tumors before the initiation of chemotherapy and suggest an association between GRP78 positivity and shorter TTR [hazard ratio (HR), 1.78; P = 0.16]. Interestingly, subgroup analysis reveals that the HR for the GRP78-positive group increased significantly among patients who did not receive further taxane treatment (HR, 3.00; P = 0.022) and among mastectomy patients (HR, 3.33; P = 0.027). The HR was even stronger among mastectomy patients who did not receive further taxane treatment (HR, 4.82; P = 0.010). The use of GRP78 as a predictor for chemoresponsiveness and the potential interaction of GRP78 and/or the UPR pathways with taxanes warrant larger studies. (Cancer Res 2006; 66(16): 7849-53)

This article has been cited by other articles:

				D. Dong, M. Ni, J. Li, S. Xiong, W. Ye, J. J. Virrey, C. Mao, R. Ye, M. Wang, L. Pen, et al. Critical Role of the Stress Chaperone GRP78/BiP in Tumor Proliferation, Survival, and Tumor Angiogenesis in Transgene-Induced Mammary Tumor Development Cancer Res., January 15, 2008; 68(2): 498 - 505. [Abstract] [Full Text] [PDF]

				C. C. Jiang, L. H. Chen, S. Gillespie, Y. F. Wang, K. A. Kiejda, X. D. Zhang, and P. Hersey Inhibition of MEK Sensitizes Human Melanoma Cells to Endoplasmic Reticulum Stress-Induced Apoptosis Cancer Res., October 15, 2007; 67(20): 9750 - 9761. [Abstract] [Full Text] [PDF]

				P. Pyrko, A. H. Schonthal, F. M. Hofman, T. C. Chen, and A. S. Lee The Unfolded Protein Response Regulator GRP78/BiP as a Novel Target for Increasing Chemosensitivity in Malignant Gliomas Cancer Res., October 15, 2007; 67(20): 9809 - 9816. [Abstract] [Full Text] [PDF]

				G. BANHEGYI, P. BAUMEISTER, A. BENEDETTI, D. DONG, Y. FU, A. S. LEE, J. LI, C. MAO, E. MARGITTAI, M. NI, et al. Endoplasmic Reticulum Stress Ann. N.Y. Acad. Sci., October 1, 2007; 1113(1): 58 - 71. [Abstract] [Full Text] [PDF]

				H.-Q. Wang, Z.-X. Du, H.-Y. Zhang, and D.-X. Gao Different Induction of GRP78 and CHOP as a Predictor of Sensitivity to Proteasome Inhibitors in Thyroid Cancer Cells Endocrinology, July 1, 2007; 148(7): 3258 - 3270. [Abstract] [Full Text] [PDF]

				A. S. Lee GRP78 Induction in Cancer: Therapeutic and Prognostic Implications Cancer Res., April 15, 2007; 67(8): 3496 - 3499. [Abstract] [Full Text] [PDF]

				Y. Fu, J. Li, and A. S. Lee GRP78/BiP Inhibits Endoplasmic Reticulum BIK and Protects Human Breast Cancer Cells against Estrogen Starvation-Induced Apoptosis Cancer Res., April 15, 2007; 67(8): 3734 - 3740. [Abstract] [Full Text] [PDF]